Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28848247 | 0.83 | CYP11B1 (0.48) | CYP11B1CYP11B2QPCT | |
| SCHEMBL3577086 | 0.81 | ALDH1A1 (0.41) | CYP11B1CYP11B2QPCTSMN1; SMN2 | |
| SCHEMBL13031367 | 0.79 | LMNA (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL25311885 | 0.79 | CYP11B1 (0.48) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL4489945 | 0.79 | CYP11B1 (0.48) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL3978013 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL1178676 | 0.78 | CYP19A1 (0.39) | CYP11B1CYP11B2QPCT | |
| SCHEMBL17410493 | 0.76 | RAB9A (0.52) | CYP11B1CYP11B2QPCTSMN1; SMN2 | |
| SCHEMBL25854022 | 0.75 | NPC1 (0.43) | CYP11B1CYP11B2QPCTSMN1; SMN2 | |
| SCHEMBL13048283 | 0.75 | CYP11B1 (0.47) | CYP11B1CYP11B2QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| CN-100347169-C | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-11-07 | — | — | CN | disclosed |
| CN-100345844-C | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| US-20040034046-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | US | disclosed |
| CN-1471527-A | Quinazoline derivatives | — | 2004-01-28 | — | — | CN | disclosed |
| CN-1434821-A | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | CYP11B1 878/4885CYP11B2 478/4885QPCT 20/4885 |
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | CYP11B1 716/4885CYP11B2 712/4885QPCT 215/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | CYP11B1 1113/4885CYP11B2 678/4885QPCT 15/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | CYP11B1 1210/4885CYP11B2 806/4885QPCT 53/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | CYP11B1 878/4885CYP11B2 478/4885QPCT 20/4885 |
| US-20040034046-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | CYP11B1 608/4885CYP11B2 300/4885QPCT 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.